Abridge has raised $300 million in a Series E funding round led by Andreessen Horowitz (a16z), with participation from Khosla Ventures. The Pittsburgh-based company is scaling its AI platform to support care delivery and reimbursement directly within medical conversations.
This fresh capital will help Abridge further expand its footprint across the U.S., where it already partners with more than 150 enterprise health systems. The funds mark a major step in advancing what Abridge calls "Care Intelligence"—the ability to make every clinical conversation actionable in real time.
The U.S. healthcare system spends nearly $1.5 trillion annually on administrative costs, much of which is tied to clinical documentation and billing. These processes are often complicated, manual, and delayed—contributing to physician burnout and slowing down reimbursement.
Abridge addresses this by embedding revenue cycle logic directly into the clinical workflow. Its AI models are trained to understand the diverse documentation and billing requirements for different specialties and patient types, capturing necessary information as the conversation unfolds.
The new funding will enable Abridge to eliminate the back-and-forth between clinicians and billing teams, helping health systems operate more efficiently. By translating medical conversations into structured, compliant documentation in real time, Abridge supports faster, more accurate claim submissions.
The company plans to invest in scaling its Contextual Reasoning Engine, which supports the latest CMS-HCC guidelines and helps ensure every relevant diagnosis is coded with supporting evidence—minimizing claim denials and audit risk.
Founded by Dr. Shiv Rao, Abridge started with the mission to simplify clinical documentation. Over time, the company has grown into a trusted partner for academic institutions, federally qualified health centers (FQHCs), and large health systems alike. Its platform is now used in over 50 million medical conversations annually, covering 55 specialties and 28 languages.
More than 90% of clinicians who begin using Abridge continue to rely on it daily. In many cases, organizations report a 60–70% reduction in clinician burnout—evidence of the platform’s impact not only on operations but also on workforce well-being.
Alongside a16z and Khosla Ventures, Abridge’s broader investor base sees a healthcare future where documentation no longer drags down the care experience. Instead, care teams can focus more on people—and less on paperwork—thanks to smarter systems working in the background.
“Abridge has both the vision and velocity to create lasting, systemic change, and we are thrilled to be part of their journey,” said David George, General Partner at a16z Growth.
